Methods and tools for identifying compounds which modulate atherosclerosis by impacting LDL-proteoglycan binding
AssigneeThe Regents of the University of California
InventorsThomas Innerarity, Jan Boren
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe Regents of the University of California
InventorsThomas Innerarity, Jan Boren
Estimating the term…
The present invention relates to the study and control of atherosclerosis through the modulation of LDL-proteoglycan binding at Site B (amino acids 3359-3369) of the apo-B100 protein in LDL. The invention encompasses methods of identifying compounds which modulate LDL-proteoglycan binding, methods of identifying compounds which modulate atherosclerotic lesion formation, and methods of modulating the formation of atherosclerotic lesions. The invention also encompasses mutant apo-B100 proteins and LDL which exhibit reduced proteoglycan binding while maintaining LDL-receptor binding, polynucleotides which encode these apo-B100 proteins, as well as cells and animals which express the mutant apo-B100 proteins.
A method for identifying compounds that affect LDL-proteoglycan binding, comprising the steps of:
The method according to claim 11, further comprising the step of:
A apo-B100 protein comprising a proteoglycan−receptor+ mutation in Site B.
Dependencies are inferred from the claim text.